Articles tagged "Adverse effects"

2016 American Transplant Congress
Long-Term vs Short-Term Valganciclovir Prophylaxis Use for Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Living Related Liver Transplantation.
T. Ueno,¹ H. Yamanaka,¹ Y. Takama,¹ N. Tanaka,¹ Y. Tazuke,¹ K. Bessho,² H. Okuyama.¹
¹Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan; ²Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
[Purpose] Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections are the most important viral infections in pediatric patients with transplant. Valganciclovir (VGCV) has been used as…
2016 American Transplant Congress
Urgent Kidney Transplantation as Successful Treatment of Calciphylaxis in Three Patients with End-Stage Kidney Failure.
E. Nordheim,¹ D. Dahle,¹ I. Syse,¹ A. Åsberg,^1,2 A. Reisæter,¹ H. Holdaas,¹ T. Jenssen,^1,3 A. Hartmann.^1,4
¹Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway; ²Shool of Pharmacy, University of Oslo, Oslo, Norway; ³Kidney, Arctic University of Tromsø, Tromsø, Norway; ⁴Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway.
Background: Calciphylaxis often referred to as calcific uremic arteriolopathy (CUA) is a rare and serious complication with limited treatment options. Kidney transplantation restores kidney function…
2016 American Transplant Congress
Anti-Thymocyte Globulin Induced Thrombocytopenia and Bleeding After Kidney Transplantation.
M. Dokus,¹ A. Patel,¹ J. Iuppa,² E. Venniro,³ A. Danzig,¹ J. Cooley,² J. Taylor,³ R. Kashyap,¹ M. Orloff.¹
¹Department of Surgery, Division of Transplant and Hepatobiliary Surgery, University of Rochester, Rochester, NY; ²Department of Pharmacy, University of Rochester, Rochester, NY; ³Department of Medicine, Division of Nephrology, University of Rochester, Rochester, NY.
Background: Bleeding is a significant challenge after renal transplantation. Anti-thymocyte globulin (ATG) induced thrombocytopenia may increase bleeding after kidney transplantation (KTx), but this association has…
2016 American Transplant Congress
Predictive Model for Medication Errors in a Chronic Kidney Transplant Clinic.
K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
¹Pharmacy, The Medical University of South Carolina, Charleston, SC; ²Transplant Nephrology, The Medical University of South Carolina, Charleston, SC.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to create a model to…
2016 American Transplant Congress
Evaluation of the Toxicity Profile of Proteasome Inhibitor-Based Therapy for Antibody Mediated Rejection.
A. Leino,¹ A. Lichvar,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,¹ F. Paterno,¹ R. Alloway,¹ A. Shields,^1,2 E. Woodle.¹
¹U of Cinncinati, Cincinnati; ²The Christ Hospital, Cincinnati.
Background: Experience with bortezomib (BTZ) antibody mediated rejection (AMR) therapy has progressively increased over the past few years. The BTZ toxicity profile in the transplant…
2016 American Transplant Congress
Pharmacist Impact on Medication Errors in a Chronic Kidney Transplant Clinic.
K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
¹Pharmacy, The Medical University of South Carolina, Charleston, SC; ²Transplant Nephrology, The Medical University of South Carolina, Charleston, South Carolina.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to assess the impact of…
2016 American Transplant Congress
Simulating Alternative Bayesian Criteria to Identify Transplant Center Performance Outliers.
J. Schold,¹ C. Miller,¹ M. Henry,² L. Buccini,¹ S. Flechner,¹ D. Goldfarb,¹ E. Poggio,¹ K. Andreoni.³
¹Cleveland Clinic, Cleveland, OH; ²Ohio State University, Columbus, OH; ³University of Florida, Gainesville, FL.
The newly constructed Bayesian models to evaluate transplant center performance were implemented in 2014. The rates and impact of the assumptions used for flagging centers…
2016 American Transplant Congress
High-Risk Pharmacogenetic (PGx) Variants in Kidney Transplant (tx) Recipients.
D. Berglund,¹ D. Schladt,² K. Sanghavi,¹ W. Guan,¹ B. Wu,¹ C. Dorr,³ R. Remmel,¹ R. Mannon,⁴ A. Matas,¹ W. Oetting,¹ A. Israni,³ P. Jacobson,¹ DeKAF Genomics Investigators.
¹UofMN, Mpls; ²MMRF, Mpls; ³HCMC, Mpls; ⁴UAB, Birmingham.
Kidney tx recipients carry a high burden of comorbidities, and some of the medications for these conditions have genetic predictors of efficacy and toxicity. These…
2016 American Transplant Congress
Evolving to Everolimus: A Safe and Effective Option for Pancreas Transplant.
S. Yeager, A. Carlson, C. Truax, N. Kenyon, F. Ahmed, J. Corbett, F. Shihab, L. Smith.
University of Utah Health Care, Salt Lake City, UT.
Although everolimus is an attractive option for conversion therapy in pancreas tx pts that experience SE's of commonly used immunosuppression, TAC and MPA, there is…
2016 American Transplant Congress
Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.
F. Shihab,¹ Y. Qazi,² S. Mulgaonkar,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ D. Shaffer.⁶
¹University of Utah, Salt Lake City, UT; ²University of Southern California, Los Angeles, CA; ³Barnabas Health, West Orange, NJ; ⁴Novartis Pharmaceuticals Corporation, East Hannover, NJ; ⁵California Pacific Medical Center, San Francisco, CA; ⁶Vanderbilt University, Nashville, TN.
We assessed the incidence of post-transplant biopsy-proven acute rejection (BPAR), graft loss and other adverse events (AEs) associated with everolimus (EVR) and tacrolimus (TAC) exposure…